Moderna, Inc. Stock Berne S.E.

Equities

0QF

US60770K1079

Biotechnology & Medical Research

Delayed Berne S.E. 12:00:00 2024-04-15 EDT 5-day change 1st Jan Change
96.41 CHF +1.01% Intraday chart for Moderna, Inc. -39.82% -47.70%

Financials

Sales 2024 * 4.15B 3.71B 5.68B Sales 2025 * 4.81B 4.3B 6.58B Capitalization 46.56B 41.62B 63.68B
Net income 2024 * -2.7B -2.41B -3.69B Net income 2025 * -2.05B -1.84B -2.81B EV / Sales 2024 * 9.7 x
Net cash position 2024 * 6.25B 5.59B 8.55B Net cash position 2025 * 4.17B 3.73B 5.7B EV / Sales 2025 * 8.81 x
P/E ratio 2024 *
-17.9 x
P/E ratio 2025 *
-23.8 x
Employees 5,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.44%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.01%
Current month-47.70%
Current year-47.70%
More quotes
3 years
96.41
Extreme 96.40800000
184.33
5 years
96.41
Extreme 96.40800000
184.33
10 years
96.41
Extreme 96.40800000
184.33
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 11-02-28
Director of Finance/CFO 47 22-09-05
President 48 12-12-31
Members of the board TitleAgeSince
Director/Board Member 65 18-05-31
Director/Board Member 74 20-06-30
Director/Board Member 67 19-12-10
More insiders
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
125.1 USD
Average target price
145.9 USD
Spread / Average Target
+16.59%
Consensus